CapsoVision Inc shares are up 44.24%, reaching a 52-week high of $18.04 in pre-market trading. This significant increase follows a remarkable rise of 52.88% in after-hours trading, driven by positive developments within the company.
The surge is attributed to the appointment of David Garcia as Senior Vice President of Finance, effective November 3. His extensive experience in financial management is expected to enhance CapsoVision's growth strategy and development pipeline, as emphasized by CEO Johnny Wang. This leadership change comes amid broader market weakness, with the Nasdaq-100 down 0.61% and the S&P 500 down 0.42%, suggesting sector rotation as investors seek opportunities in companies with strong fundamentals.
This leadership transition could position CapsoVision for further growth, especially given its recent performance and market capitalization of $552.75 million. Investors will be keen to see how Garcia's expertise translates into strategic initiatives that could drive the company's future success.
Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CV is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.260
Low
7.00
Averages
10.50
High
14.00
Current: 5.260
Low
7.00
Averages
10.50
High
14.00
Benchmark
Speculative Buy
upgrade
$5 -> $14
2025-12-31
Reason
Benchmark
Price Target
$5 -> $14
AI Analysis
2025-12-31
upgrade
Speculative Buy
Reason
Benchmark raised the firm's price target on CapsoVision to $14 from $5 and keeps a Speculative Buy rating on the shares after the company announced that it submitted a 510(k) application to the FDA for its proprietary AI-assisted module for the CapsoCam Plus. The firm, which believes the company has a competitive advantage with its in-house AI team and a growing image data trove from consenting patient clinical data, argues that the company deserves an above-average multiple compared to its comp group because of its above-average revenue growth and predicted gross margins.
Roth Capital
NULL
to
Buy
initiated
$7
2025-11-04
Reason
Roth Capital
Price Target
$7
2025-11-04
initiated
NULL
to
Buy
Reason
Roth Capital resumed coverage of CapsoVision with a Buy rating and $7 price target. The firm says the two label expansions in December 2024, to include pediatrics as young as two and remote ingestions, will help to accelerate adoption of the company's "best-in-class" device. It sees clearance of Gen 1 CapsoCam Colon as well as submissions for CapsoVision's small bowel artificial intelligence module as additional catalysts for the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CV
Unlock Now
Roth Capital
Jason Wittes
Buy
initiated
$6
2025-07-28
Reason
Roth Capital
Jason Wittes
Price Target
$6
2025-07-28
initiated
Buy
Reason
Roth Capital analyst Jason Wittes initiated coverage of CapsoVision with a Buy rating and $6 price target. The firm believes the company is progressing advanced imaging and artificial intelligence implementation with its capsule endoscopy platform for gastrointestinal screening and diagnosis. CapsoVision is positioned for 19.5% growth in 2025 with its initial small bowel indication, and also recently submitted 510(k) approval for the much larger colon indication, the analyst tells investors in a research note. It sees this boosting revenue growth in 2026.
Benchmark
NULL -> Speculative Buy
initiated
$5
2025-07-28
Reason
Benchmark
Price Target
$5
2025-07-28
initiated
NULL -> Speculative Buy
Reason
Benchmark initiated coverage of CapsoVision with a Speculative Buy rating and $5 price target.
About CV
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
